证券代码：600201 证券简称：生物股份 公告编号：临 2026-001 金宇生物技术股份有限公司 关于大股东首次增持公司股份暨 增持计划实施进展的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股东名称 | 持股数量 （股） | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | | 内蒙古金宇生 | | | 张翀宇持有生物控股 39.00%股 | | 物控股有限公 | 122,304,000 | 11.00% | 权，张竞持有生物控股 51.93% | | 司 | | | 股权，张翀宇与张竞系父女关 | | 张翀宇 | 23,003,826 | 2.07% | 系，二人合计持有生物控股 | | 张竞 | 6,132,742 | 0.55% | 90.93%股权，系生物控股实际 | | 合计 | 151,440,568 | 13．62% | 控制人 | 二、增持计划的实施进展 | 增持主体名称 | 内蒙古金宇生物控股有限公司 | | --- | - ...

Group 1: Fundraising Overview - The company raised a total of RMB 4,581,500,000 through its initial public offering, with a net amount of RMB 4,341,379,433.74 after deducting issuance costs [2] - The funds were deposited into a special account for management and were subject to a tripartite supervision agreement with the sponsor and the bank [2][3] Group 2: Fund Allocation and Project Adjustments - The company decided to terminate five research sub-projects and reallocate the unused funds to other ongoing and new sub-projects, including an investment of RMB 10 million to its wholly-owned subsidiary for a new flu vaccine project [3] - A special account was established for the "high-dose flu virus split vaccine" project, adhering to the principle of "special account storage and special fund usage" [4] Group 3: Tripartite Supervision Agreement - The tripartite agreement involves the company, its subsidiary, and the bank, ensuring that the funds are used exclusively for the designated project [5] - The agreement stipulates that any withdrawal exceeding 20% of the net fundraising amount must be reported to the sponsor within five working days [7] Group 4: Share Buyback Progress - The company plans to repurchase shares using between RMB 10 million and RMB 20 million of surplus funds, with a maximum price of RMB 38.00 per share [11] - As of December 31, 2025, the company had repurchased 384,899 shares, accounting for approximately 0.092% of the total share capital, with a total expenditure of RMB 10,789,216.56 [13]

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

附件下载 公示期：2026年1月5日至2026年1月14日 联系邮箱：jyzjz@samr.gov.cn ...

Core Insights - The "2025 National Food Industry Technological Progress Work Conference and the Release of the 2025 China Food Industry Development Research Report" was held in Beijing, where the report and the list of "2025 China Food Industry Key Enterprises 500" were released [1] - The report aims to guide food enterprises in China to adapt to new development stages and promote high-quality development in the food industry [2][3] Group 1: Key Enterprises - Three companies from Dezhou, including Gubeichun Group Co., Ltd., Shandong Bailong Chuangyuan Biotechnology Co., Ltd., and Baolingbao Biology Co., Ltd., were included in the key enterprises list [1] - The list is the first of its kind in the food industry, aimed at analyzing and summarizing the growth experiences of these key enterprises [2][3] Group 2: Research and Analysis - Starting from 2025, the association will conduct annual analyses of the 500 key food enterprises, focusing on their growth and their roles in regional economies and industry development [3] - The selection of these enterprises is based on their voluntary application and the revenue standards set for 2024 [3]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

证券代码：600201 证券简称：生物股份 公告编号：临 2025-064 金宇生物技术股份有限公司 关于股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 内蒙古金宇生物控股有限公司（以下简称"生物控股"）持有金宇生物技 术股份有限公司（以下简称"本公司"、"公司"）股份 122,304,000 股， 占本公司总股本的 11.00%。本次股份质押后，其累计质押本公司股份数 量为 27,000,000 股，占生物控股持有本公司股份数量的 22.08%。 一、公司股份质押情况 公司于 2025 年 12 月 31 日接到股东生物控股函告，获悉其将所持有的本公司 8,400,000 股无限售流通股股票质押给中国民生银行股份有限公司呼和浩特分行， 并在中国证券登记结算有限责任公司办理完成了证券质押登记手续，具体事项如 下： 他保障用途。 3、股东累计质押股份情况 截至公告披露日，生物控股及其一致行动人累计质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | | ...

Group 1 - The core viewpoint of the news is that Jinyu Biological Technology Co., Ltd. has seen a stock price increase of 1% to 15.15 CNY per share, with a trading volume of 223 million CNY and a market capitalization of 16.843 billion CNY as of December 31 [1] - The company, established on March 13, 1993, and listed on January 15, 1999, primarily engages in the research, production, and sales of veterinary biological products, with main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Group 2 - From the perspective of major fund holdings, one fund under China Merchants Fund has heavily invested in Jinyu Biological, specifically the China Merchants CSI Animal Husbandry ETF (516670), which increased its holdings by 834,000 shares to a total of 3.6029 million shares, representing 3.95% of the fund's net value, making it the eighth-largest holding [2] - The China Merchants CSI Animal Husbandry ETF (516670) was established on March 18, 2021, with a current scale of 879 million CNY, achieving a year-to-date return of 14.24% and a one-year return of 12.42%, while its performance since inception shows a loss of 29.02% [2]

Group 1 - A total of 88 stocks in the A-share market experienced block trading today, with a total transaction value of 2.359 billion yuan [1] - The top three stocks by transaction value were Giant Network at 302 million yuan, Muyuan Foods at 187 million yuan, and New Asia Electronics at 130 million yuan [1] - Among the stocks, 4 were traded at par, 4 at a premium, and 80 at a discount; the highest premium rates were for Shenghua Biotech at 8.2%, Vanke A at 2.6%, and Jinko Power at 1.07% [1] Group 2 - The top buying amounts from institutional special seats were led by Giant Network at 302 million yuan, followed by Changchuan Technology at 105 million yuan and Tuojing Technology at 103 million yuan [2] - The top selling amounts from institutional special seats were led by Jinko Power at 99.4 million yuan and Zhongji Xuchuang at 16.36 million yuan [2]

12月30日，生物股份大宗交易成交14.79万股，成交额240.04万元，占当日总成交额的0.4%，成交价 16.23元，较市场收盘价15元溢价8.2%。 ...